- Orgenesis has entered into an agreement with Williamsburg Venture Holdings for an equity line of credit worth up to $5 million.
- The company will receive an initial $750,000, with the remainder available over 24 months.
Orgenesis, a global biotech company has secured a $5 million equity line of credit from Williamsburg Venture Holdings. The deal provides $750,000 upon registration effectiveness, with a further $4.25 million accessible over two years. The funding will support Orgenesis’ initiatives in advancing its cell and gene therapy (CGT) programs.
Vered Caplan, CEO of Orgenesis, expressed gratitude for the investment, noting it will accelerate the development and commercialization of their CGT pipeline, particularly through their proprietary POCare platform. This aligns with their goal to democratize access to life-saving therapies.
The terms allow Orgenesis to draw funds flexibly, with the purchase price set at 90% of the average market price.